Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HighTide Therapeutics, Inc.
君圣泰医药
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2511)

BUSINESS UPDATE
COMMENCING RESEARCH COOPERATION WITH INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES TO EXPLORE THE METABOLIC AND RENAL BENEFITS POTENTIAL OF INNOVATIVE DRUGS

This announcement is made by HighTide Therapeutics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board (the "**Board**") of directors of the Company announces that Shenzhen HighTide Biopharmaceutical Ltd., a wholly-owned subsidiary of the Group, has commenced a collaborative project with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (the "**IMB**") to evaluate the therapeutic potential of the Group's core product, HTD1801, for treatment of type 2 diabetes mellitus with chronic kidney disease (CKD with T2DM). This project has recently been approved by the Chinese Academy of Medical Sciences. Both parties will jointly conduct mechanism and clinical research targeting on indication of CKD with T2DM, striving to explore innovative treatment solutions with comprehensive interventional value.

OVERVIEW OF COOPERATION

Project Name: Research of Isoquinoline-based Innovative Drug Driven by Neg-Entropy Theory: Glucose-lowering Mechanism and Clinical Validation

Leading Unit: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

Collaborating Unit: Shenzhen HighTide Biopharmaceutical Ltd.

This cooperation focuses on the development of glyco-renal metabolic-related diseases, by tapping into IMB's resource advantages in drug research and medical science, in combination with the Group's core competitiveness and product development experience in metabolic diseases. The efforts aim to accelerate the clinical advancement of innovative therapeutics and enhance the product application value.

Pursuant to the cooperation agreement, both parties will jointly conduct mechanism research on isoquinoline-based new drug, and advance the clinical development to expand the clinical applications in CKD with T2DM.

This cooperation will accelerate the clinical progress of the Group's core project, expand its strategic research and development arrangement, and further enrich the product pipeline, providing strong support for the Company's continuous innovation and long-term development in metabolic disease treatment.

ABOUT HTD1801

HTD1801, HighTide's lead drug candidate, is also the primary product for this cooperation development. It is a first-in-class orally delivered, gut-liver anti-inflammatory metabolic modulator with a unique dual mechanism of action that activates AMPK and inhibits the NLRP3 inflammasome. Clinical trials conducted globally have shown that HTD1801 can concurrently improve indicators such as blood glucose, lipid, kidney function, body weight, liver function, cardiovascular health, and inflammation, demonstrating its potential for co-morbidity treatment across multiple indications including type 2 diabetes mellitus, chronic kidney disease, obesity, dyslipidemia, and fatty liver.

ABOUT INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES

Established in 1956 as China's highest medical research institution and leading medical education institution, the Chinese Academy of Medical Sciences takes on the mission of leading China's medical science and education development and safeguarding the public health, and leads the medical industry and has made significant contributions to the establishment and development of China's modern scientific medical system.

The Institute of Medicinal Biotechnology (IMB) is a direct institute under the Chinese Academy of Medical Sciences, focusing on key areas in microbial drugs, anti-infective drugs, and biotechnical drug research, and maintains leading research advantages in relevant disciplines and fields in China. In possession of a comprehensive new drug research system, the IMB has made important progress in new drug research and development in fields such as anti-infection, anti-metabolic syndrome, and anti-cancer, and has therefore become an indispensable national strategic scientific and technological force.

ABOUT HIGHTIDE THERAPEUTICS, INC.

HighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across metabolic diseases. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials. HTD1801, HighTide's lead drug candidate, received two Fast Track designations from the United States Food and Drug Administration and one Orphan Drug designation. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that HTD1801 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, August 12, 2025

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. LI Jin and Mr. HUNG Tak Wai as independent non-executive Directors.